Patents by Inventor Carl Jeffrey Lacey

Carl Jeffrey Lacey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9512068
    Abstract: Augmented or synergized anti-inflammatory constructs are disclosed including terpenes covalently conjugated with other anti-inflammatory molecules such as nonsteroidal anti-inflammatory drugs, vanilloids, amino acids and polyamines; and anti-inflammatory molecules covalently conjugated with specific amino acids. For the latter, further conjugation with a choline bioisostere further augments the anti-inflammatory activity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, LEHIGH UNIVERSITY
    Inventors: Jeffrey D. Laskin, Ned D. Heindel, Diane E. Heck, Carl Jeffrey Lacey, Sherri C. Young
  • Patent number: 9422233
    Abstract: Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: August 23, 2016
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, LEHIGH UNIVERSITY
    Inventors: Jeffrey D. Laskin, Ned D. Heindel, Carl Jeffrey Lacey, Abhilash N. Pillai, Marion Gordon, Diane E. Heck
  • Publication number: 20160031804
    Abstract: Augmented or synergized anti-inflammatory constructs are disclosed including terpenes covalently conjugated with other anti-inflammatory molecules such as nonsteroidal anti-inflammatory drugs, vanilloids, amino acids and polyamines; and anti-inflammatory molecules covalently conjugated with specific amino acids. For the latter, further conjugation with a choline bioisostere further augments the anti-inflammatory activity.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Jeffrey D. Laskin, Ned D. Heindel, Diane E. Heck, Carl Jeffrey Lacey, Sherri C. Young
  • Patent number: 8343971
    Abstract: This application relates to pharmacologically-active vanilloid compounds which are useful for the treatment of various anti-inflammatory states characterized by inhibition of FAAH, such as, Alzheimer's dementia, Parkinson's disease, depression, pain, rheumatoid arthritis, pathophysiology of mood disorders, multiple sclerosis, and inflammation, or antagonism of TRPV1, such as, for example, Huntington's disease, hypertension, arthritis, allergic airway inflammation, Crohn's disease, ulcerative colitis, and neuropathic pain.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 1, 2013
    Assignees: Rutgers, The State University of New Jersey, The University of Medicine and Dentistry of New Jersey, Lehigh University
    Inventors: Jeffrey D. Laskin, Diane E. Heck, Carl Jeffrey Lacey, Erik Aponte, Mou-Tuan Huang, Ned D. Heindel
  • Publication number: 20120252891
    Abstract: Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye.
    Type: Application
    Filed: March 16, 2012
    Publication date: October 4, 2012
    Applicants: University of Medicine and Dentistry of New Jersey, Lehigh University, Rutgers, The State University of New Jersey
    Inventors: Jeffrey D. Laskin, Ned D. Heindel, Carl Jeffrey Lacey, Abhilash N. Pillai, Marion Gordon, Diane E. Heck
  • Publication number: 20120059007
    Abstract: This application relates to pharmacologically-active vanilloid compounds which are useful for the treatment of various anti-inflammatory states characterized by inhibition of FAAH, such as, Alzheimer's dementia, Parkinson's disease, depression, pain, rheumatoid arthritis, pathophysiology of mood disorders, multiple sclerosis, and inflammation, or antagonism of TRPV1, such as, for example, Huntington's disease, hypertension, arthritis, allergic airway inflammation, Crohn's disease, ulcerative colitis, and neuropathic pain.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 8, 2012
    Inventors: Jeffrey D. Laskin, Diane E. Heck, Carl Jeffrey Lacey, Erik Aponte, Mou-Tuan Huang, Ned D. Heindel
  • Patent number: 8039501
    Abstract: This invention provides compounds having the structural formula: wherein: R1 is an acyl or sulfonyl group, R2 is an acyl group selected from the group consisting of acyl groups derived from cycloaliphatic, aromatic or heterocyclic monocarboxylic acids, imidazolylcarbonyl and triazolylcarbonyl, and R3 is hydrogen or an amino-protecting group, a stereoisomer thereof, a solvate thereof, or a salt thereof, being useful as anti-inflammatory agents and anti-cancer agents.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: October 18, 2011
    Assignee: Universiteit Gent
    Inventors: Wim Vanden Berghe, Karolien De Bosscher, Serge Van Calenbergh, Guy Haegeman, Carl Jeffrey Lacey
  • Publication number: 20090029999
    Abstract: This invention provides compounds having the structural formula: wherein: R1 is an acyl or sulfonyl group, R2 is an acyl group selected from the group consisting of acyl groups derived from cycloaliphatic, aromatic or heterocyclic monocarboxylic acids, imidazolylcarbonyl and triazolylcarbonyl, and R3 is hydrogen or an amino-protecting group, a stereoisomer thereof, a solvate thereof, or a salt thereof, being useful as anti-inflammatory agents and anti-cancer agents.
    Type: Application
    Filed: June 23, 2008
    Publication date: January 29, 2009
    Applicant: UNIVERSITEIT GENT
    Inventors: Wim VANDEN BERGHE, Karolien DE Bosscher, Serge Van Calenbergh, Guy Haegeman, Carl Jeffrey Lacey, Valerie Gossye, Ruben Hoya Arias, Sarah Gerlo